
## Kaori Matsumoto

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1213082/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Role of human flavin-containing monooxygenase (FMO) 5 in the metabolism of nabumetone: Baeyer–Villiger oxidation in the activation of the intermediate metabolite, 3-hydroxy nabumetone, to the active metabolite, 6-methoxy-2-naphthylacetic acid <i>inÂvitro</i> . Xenobiotica, 2021, 51, 155-166.	1.1	11
2	A metabolic pathway for the prodrug nabumetone to the pharmacologically active metabolite, 6-methoxy-2-naphthylacetic acid (6-MNA) by non-cytochrome P450 enzymes. Xenobiotica, 2020, 50, 783-792.	1.1	8
3	Reductive metabolism of nabumetone by human liver microsomal and cytosolic fractions: exploratory prediction using inhibitors and substrates as marker probes. European Journal of Drug Metabolism and Pharmacokinetics, 2015, 40, 127-135.	1.6	11
4	In Vitro Characterization of the Cytochrome P450 Isoforms Involved in the Metabolism of 6-Methoxy-2-napthylacetic Acid, an Active Metabolite of the Prodrug Nabumetone. Biological and Pharmaceutical Bulletin, 2011, 34, 734-739.	1.4	17